6533b82cfe1ef96bd128f4ea

RESEARCH PRODUCT

Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

Ghezzi AAnnovazzi PCocco ECoarelli GLugaresi ARovaris MPatti FCapello ERodegher MeMoiola LMalucchi SSalemi GDe Rossi NProvinciali LPerini PBergamaschi RScarpini ELus GGallo ATola MrAmato MpRottoli MrBianchi AMs Study Group Italian Society Of NeurologyGiancarlo Comi

subject

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosismedicine.medical_treatmentendovascular multiple sclerosis treatment venousDermatologyBalloon dilatationCohort StudiesSurveys and QuestionnairesMedicineHumansIn patientEndovascular treatmentAdverse effectBeneficial effectsbusiness.industryMultiple sclerosisEndovascular ProceduresStentBrainRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryPsychiatry and Mental healthTreatment OutcomeSpinal CordVenous InsufficiencySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessMultiple sclerosis CCSVI Endovascular treatmentFollow-Up Studies

description

Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of the study is to evaluate the outcome and safety of ET in Italian MS patients. Italian MS centers that are part of the Italian MS Study Group were all invited to participate to this retrospective study. A structured questionnaire was used to collect detailed clinical data before and after the ET. Data from 462 patients were collected in 33 centers. ET consisted of balloon dilatation (93 % of cases) or stent application. The mean follow-up duration after ET was 31 weeks. Mean EDSS remained unchanged after ET (5.2 vs. 4.9), 144 relapses occurred in 98/462 cases (21 %), mainly in RR-MS patients. Fifteen severe adverse events were recorded in 3.2 % of cases. Given the risk of severe adverse events and the lack of objective beneficial effects, our findings confirm that at present ET should not be recommended to patients with MS.

yearjournalcountryeditionlanguage
2013-01-01
10.1007/s10072-013-1300-5.